

**Supplementary information, Table S1. Characteristics of TNBC patients in the FUSCC cohort.**

Characteristic	Overall (n, %)	High genetic ITH (n, %)	Low genetic ITH (n, %)	p	High histologic ITH (n, %)	Low histologic ITH (n, %)	p
<b>Total</b>	260 (100.0)	115 (44.2)	145 (55.8)		130 (50.0)	130 (50.0)	
<b>Age (years)</b>				<b>0.856</b>			<b>1.000</b>
≤40	27 (10.4)	11 (9.6)	16 (11.0)		13 (10.0)	14 (10.8)	
>40	233 (89.6)	104 (90.4)	129 (89.0)		117 (90.0)	116 (89.2)	
<b>Menopause</b>				<b>0.438</b>			<b>0.525</b>
Yes	160 (61.5)	76 (66.1)	84 (57.9)		76 (58.5)	84 (64.6)	
No	97 (37.3)	38 (33.0)	59 (40.7)		52 (40.0)	45 (34.6)	
Unknown	3 (1.2)	1 (0.9)	2 (1.4)		2 (1.5)	1 (0.8)	
<b>Grade</b>				<b>0.072</b>			<b>0.155</b>
2	45 (17.3)	20 (17.4)	25 (17.2)		17 (13.1)	28 (21.5)	
3	187 (71.9)	77 (67.0)	110 (75.9)		100 (76.9)	87 (66.9)	
Unknown	28 (10.8)	18 (15.6)	10 (6.9)		13 (10.0)	15 (11.6)	
<b>Tumor size</b>				<b>0.833</b>			<b>0.364</b>
≤2cm	92 (35.4)	42 (36.5)	50 (34.5)		50 (38.5)	42 (32.3)	
>2cm	168 (64.6)	73 (63.5)	95 (65.5)		80 (61.5)	88 (67.7)	

<b>Lymph node status</b>				<b>0.372</b>		<b>0.899</b>
Negative	156 (60.0)	73 (63.5)	83 (57.2)		77 (59.2)	79 (60.8)
Positive	104 (40.0)	42 (36.5)	62 (42.8)		53 (40.8)	51 (39.2)
<b>Ki-67</b>				<b>0.161</b>		<b>0.105</b>
≤20%	36 (13.8)	21 (18.3)	15 (10.3)		21 (16.2)	15 (11.5)
>20%	221 (85.0)	93 (80.9)	128 (88.3)		106 (81.5)	115 (88.5)
Unknown	3 (1.2)	1 (0.8)	2 (1.4)		3 (2.3)	0 (0.0)
<b>Histology</b>				<b>0.214</b>		<b>0.245</b>
IDC	240 (92.3)	103 (89.6)	137 (94.5)		117 (90.0)	123 (94.6)
Others	20 (7.7)	12 (10.4)	8 (5.5)		13 (10.0)	7 (5.4)
<b>OS status</b>						
Alive	223 (85.8)	93 (80.9)	130 (89.7)		109 (83.8)	114 (87.7)
Deceased	37 (14.2)	22 (19.1)	15 (10.3)		21 (16.2)	16 (12.3)
<b>RFS status</b>						
non-Relapsed	208 (80.0)	84 (73.0)	124 (85.5)		99 (76.2)	109 (83.8)
Relapsed	52 (20.0)	31 (27.0)	21 (14.5)		31 (23.8)	21 (16.2)
<b>DMFS status</b>						
non-Metastatic	212 (81.5)	86 (74.8)	126 (86.9)		102 (78.5)	110 (84.6)

Metastatic	48 (18.5)	29 (25.2)	19 (13.1)	28 (21.5)	20 (15.4)
<b>Survival (months)</b>					
Median follow-up	86.47 (71.07-100.39)	83.20 (65.42-96.85)	88.10 (73.80-101.23)	84.97 (71.10-102.08)	87.23 (70.67-99.68)
Median OS	84.98 (66.25-98.95)	81.71 (61.85-95.46)	86.83 (71.23-99.55)	83.33 (65.92-100.62)	85.98 (66.60-98.25)
Median RFS	84.04 (55.97-97.13)	78.42 (46.70-93.88)	85.98 (62.82-99.19)	81.76 (55.87-98.50)	85.40 (60.84-97.06)
Median DMFS	84.40 (60.71-98.95)	79.38 (46.70-94.09)	86.83 (69.03-100.34)	82.15 (59.89-100.62)	85.80 (61.53-98.25)

Abbreviations: IDC, invasive ductal carcinoma; OS, overall survival; RFS, recurrence-free survival; DMFS, distant metastasis-free survival.